A Single-centre, Randomised, Double-blind, Placebo-controlled, Four-period Cross-over Study to Evaluate the Scopolamine Cognition Model in Healthy Male Subjects Using AZD1446 and Donepezil Versus Placebo.

Trial Profile

A Single-centre, Randomised, Double-blind, Placebo-controlled, Four-period Cross-over Study to Evaluate the Scopolamine Cognition Model in Healthy Male Subjects Using AZD1446 and Donepezil Versus Placebo.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Oct 2010

At a glance

  • Drugs AZD 1446 (Primary) ; Donepezil
  • Indications Cognition disorders
  • Focus Pharmacodynamics
  • Most Recent Events

    • 08 Oct 2010 Primary endpoint 'EEG changes' has not been met.
    • 12 Feb 2010 Completion is expected in the second half of 2010, according to a Targacept media release.
    • 14 Jan 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top